PATENT DOCKET 17328

Serial No. 09/550,371

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

Sheet	_1_	of	_1_

LIST OF ART CI.	LED BI ATTEICANI
ATTY. DOCKET: 17328	SERIAL NO.: 09/550,371 10/630, 206
APPLICANT: AOKI, ET AL.,	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE: April 14, 2000	GROUP: 1653

UNITED STATES PATENTS

UNITED BIRIDS I III DE LE CONTROL DE LA CONT								
*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)	
CHK	AA	6,113,915	9/5/00	AOKI	424	236		
					ļ			

FOREIGN PATENT DOCUMENTS

		200 200 1 2 1 1				
·	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (yes/a)
					 	
					ļ	
					<u> </u>	

OTHER ART

(Including Audol, 11de, Date, 1 et allent 1 ages, 5.5.)								
	T	T					•	
	┼	<u> </u>						
	+	 						
	 	 						
	 		·····					
	 							
	 	ļ.———						
	 							
	ļ	 						
	<u> </u>							
		<u> </u>						
	<u> </u>							
		l				·		
			-					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce, Patent and Trademark Office Serial No. Atty Docket No. PTO form 1449 19/630,26 09/550,371 17328 (AP) INFORMATION DISCLOSURE STATEMENT BY APPLICANT Applicant(s) Aoki et al. (Use several sheets if necessary) Group /653 Filing Date October 4, 2000 U.S. Patent Documents Filing Date Document *Examiner If Appropriate Subclass Class Name Date Number Initial First 5/26/00 CHK 6,063,768 AA AB AC AD. ΑE AF `AG AH AI AJ ΑK Foreign Patent Documents Translation Yes Subclass Country Class Date Document ÁL AM AN AO AP ART (Including Author, Title, Date, Pertinent Pages, Etc.) OTHER AQ. AR AS Date Considered 105 Examiner *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

> SUPPLEMENTAL LIST OF ART CITED BY APPLICANT

LIST	OF ARI CITED DI ATTERCENT
ATTY. DOCKET: 17328 (BOT)	SERIAL NO.: 09/550,371 10/630, 206
APPLICANT: AOKI, et al.	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATIONOF A NEUROTOXIN
FILING DATE: APRIL 14, 2000	GROUP: 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	·	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CMK	AA	6,113,915	9/5/00	AOKI	_424		
	AB						
	AC						
	AD		•				
	AE			<u> </u>			<u> </u>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
CAK	BA	WO 97/34624	9/25/97	PCT			
	BB	WO 96/33273	10/24/96	PCT			
CM	BC	WO 95/30431	11/16/95	PCT			

•			(Including Author, Title, Date, Pertinent Pages, etc.)
C	MK	CA	001031379
	7	СВ	Carruthers, A., et al., Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections, Headache, Oct. 1999:39:662-665, XP-001031356
	 	CC	Diaz, J., et al., Management of post-thoracotomy pseudoangina and myofascial pain with botulinum toxin, Anesthesi logy, V 91, No. 3, Sep 1999, pp. 877-879, XP-001031347
		CD	Silberstein, S., et al., Botulinum toxin type A as a migraine preventive treatment, Headache 2000:40:445-450, XP-002182692
C	MK	CE	Gobel, H., et al., Evidence-based medicine: botulinum toxin A in migraine and tension-type headache, Journal of Neurology, 2001 248 Supp 1: I/34-I/38, XP-002182693
			l ·

EXAMINER Comments	DATE CONSIDERED	429/05
*EXAMINER: Initial if reference considered, whether or not citation	is in conformance with MPEP 6	09; Draw line through citation if n t i
conformance and not considered. Include copy of this form with next	communication to applicant.	·

U.S.	DEP	artme	NT OF	COM	MERCE
PAT	ENT.	AND TE	RADEN	MARK	OFFICE
		O-1449			

Sheet	1	of	1

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 09/550,371 10/630, 206
APPLICANT:	Aoki et al.	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	04/14/2000	GROUP: 1646 /653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CME	AA	6,063,768	5/16/00	FIRST	-		
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
1	BA						
	BB						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CMK	CA	Cheng, Guang-Shing; Botox, Dermabrasion Treated Facial Leiomyomas; Skin & Allergy News 2000;31(3):16.
	СВ	First, E. et al.; Painful Cervical Dystonia: Response to Treatment with Botulinum Toxin; Mov Disord 1998;13(Suppl2):100.
	CC	Guyer, Barry M.; Mechanism of Botulinum Toxin in the Relief of Chronic Pain; Curr Rev Pain 1999;3(6):427-431.
	CD	Li, Yan, et al.; A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen after Reconstitution with Native Heavy Chain; Biochemistry 1994, 33, 7014-7020.
	CE	Schantz, Edward J., et al.; Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine; Microbiological Reviews Mar. 1992, pp. 80-99, Vol. 56, No. 1.
	CF	Tarsy, Daniel, et al.; Painful Cervical Dystonia: Clinical Features and Response to Treatment With Botulinum Toxin; Mov Disord 1999;14(6):1043-1045.
CAK	CG	Zhou, Liqing, et al.; Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain; Biochemistry 1995, 34, 15175-15181.
	СН	

EXAMINER DATE CONSIDERED 4/29/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. 1	DEPARTMENT OF COMMERCE
PATE	INT AND TRADEMARK OFFICE
FORM	A PTO-1449

Sheet	_1_	of	4
-------	-----	----	---

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 10/630, 266		
APPLICANT: AOKI et al.		TITLE: METHOD FOR TREATING PAIN BY PERI- PHERAL ADMINISTRATION OF A NEUROTOXIN		
FILING DATE:	(Herewith)	GROUP: 1653		

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CMK	AA	5,714,468	2/3/98	BINDER			
7	AB	5,766,605	6/16/98	SANDERS ET AL.			
Chy	AC	5,989,545	11/23/99	FOSTER ET AL.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
CMK	BA	94/15629	7/21/94	PCT		-	
	BB	96/33273	10/24/96	PCT			
7	BC	98/07864	2/26/98	PCT			
Crt	BD	99/17806	4/15/99	PCT			

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CAK Barwood, Shane, et al.; Analgesic Effects of Botulinum Controlled Clinical Trial; Developmental Medicine & Controlled Clinical Trial;		Barwood, Shane, et al.; Analgesic Effects of Botulinum Toxin A: A Randomized, Placebo- Controlled Clinical Trial; Developmental Medicine & Child Neurology, 2000; 42:116-121
	СВ	Bigalke, H., et al.; Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture; Brain Research, 360 (1985); 318-324.
	cc	Bigalke, H., et al.; Tetanus Toxin and Botulinum A. Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord; Naunyn-Schmiedeberg's Arch. Pharmacol (1981); 316:244-251.
	CD	Cheshire, et al.; Botulinum Toxin in the Treatment of Myofascial Pain Syndrome; Pain, 1994; 59(1):65-9.
CMK	CE	DiStefano, P. S., et al.; Receptor Mediated Retrograde Axonal Transport of Neurotrophic Factors is Increased After Peripheral Nerve Injury; Progress in Brain Research (1994); Vol. 103; Chapter 4; 35-42.

	001		4/29/
EXAMINER_	C/2-1	DATE CONSIDERED	1-1105
*FYAMINFR: Initia	I if reference considered	Whether or not citation is in conformance with MOED 600	b Denn line showsh size

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	2	of	4

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 10/630, 206
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERI- PHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP: 1653

OTHER ART (Continued)
(Including Author, Title, Date, Pertinent Pages, etc.)

0	MK	CF	Dixon, W. J.; Efficient Analysis of Experimental Observations; Ann. Rev. Pharmacol. Toxicol. (1980); 20:441-462.
	T	CG	
		СН	Duc, C., et al.; Ultrastructural Localization of SNAP-25 Within the Rat Spinal Cord and Peripheral Nervous System; The Journal of Comparative Neurology (1995); 356:152-163.
		CI	Fauci, A.S., et al. (Editors); <u>Harrison's Principles of Internal Medicine</u> , 14 th Edition (1998); McGraw-Hill; 2064-2065.
		C	Garner, C.G., et al.; Time Course of Distant Effects of Local Injections of Botulinum Toxin; Movement Disorders; Vol. 8, No. 1; 1993.
		CK	Habermann, E.; Inhibition by Tetanus and Botulinum A Toxin of the Release of (³ H)noradrenaline and (³ H)GABA from Rat Brain Homogenate; Experientia 44 (1988); 224-226.
		CL	Habermann, E.; I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord; Naunyn Schmiedeberg's Arch. Pharmacol.; 281, 47-56 (1974).
	•	СМ	Habermann, E., et al.; Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain; Journal of Neurochemistry; Vol. 51; No. 2 (1988); 522-527.
		CN	Hagenah, R., et al.; Effects of Type A Botulinum Toxin on the Cholinergic Transmission at Spinal Renshaw Cells and on the Inhibitory Action at Ia Inhibitory Interneurones; Naunyn-Schmiedeberg's Arch. Pharmacol.; 299, 267-272 (1977).
			Halpern, J.L., et al.; Neurospecific Binding, Internalization, and Retrograde Axonal Transport; Date Unknown; pp. 221-241.
			Johnson, E., et al.; Biomedical Aspects of Botulinum Toxin; J. ToxicolToxin Reviews; Feb. 18, 1999; 18(1):1-15.
CIYK		CQ	Jung, H. H., et al.; Expression of Neurotransmitter Genes in Rat Spinal Motoneurons After Chemodenervation with Botulinum Toxin; Neuroscience (1997); Vol. 78, No. 2; 469-479.

	002			4/201
EXAMINER	OBLI		DATE CONSIDERED	14/05
ACVARAINTED. Talaia	: F F	1 .1		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	3	of	4

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 10/639 206
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERI- PHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP: 1653

OTHER ART (Continued)

(Including Author, Title, Date, Pertinent Pages, etc.)

C	1K	CR	Kim, S. H., et al.; An Experimental Model for Peripheral Neuropathy Produced by Segmental
	/`	-	Spinal Nerve Ligation in the Rat; <u>Pain</u> , 50 (1992); 355-363.
	1	CS	Li et al.; Biochemistry; 33:7014-7020 (1994).
		СТ	Mochida, S., et al.; Impairment of Syntaxin by Botulinum Neurotoxin C ₁ or Antibodies Inhibits Acetylcholine Release but not Ca ²⁺ Channel Activity; Neuroscience (1995); Vol. 65; No. 3; 905-915.
		CU	Naumann, et al.; Botulinum Toxin Type A in the Treatment of Focal, Axillary and Palmar Hyperhidrosis and Other Hyperhidrotic Conditions; European Journal of Neurology, 1999; Vol. 6(suppl4):S3-S10 and S111-S115.
		CV	Nelson, P.G., et al.; Mouse Spinal Cord in Cell Culture. IV. Modulation of Inhibitory Synaptic Function; Journal of Neurophysiology; Vol. 40, No. 5; Sept. 1977; 1178-1187.
		CW	Osen-Sand, A., et al.; Inhibition of Axonal Growth by SNAP-25 Antisense Oligonucleotides in vitro and in vivo; Nature; 29 July 1993; Vol. 364; 445-448.
		CX	Pearce, L. B., et al.; Pharmacologic Characterization of Botulinum Toxin for Basic Science and Medicine; Toxicon (1997); Vol. 35, No. 9; 1373-1412.
		CY	Ragona, et al.; Management of Parotid Sialocele with Botulinum Toxin; Laryngoscope, 109:August 1999; p. 1344-36
		CZ	Ransom, B.R., et al.; Mouse Spinal Cord in Cell Culture. I. Morphology and Intrinsic Neuronal Electrophysiologic Properties; Journal of Neurophysiology; Vol. 40, No. 5; Sept. 1977; 1132-1150.
		DA	Ransom, B.R., et al.; Mouse Spinal Cord in Cell Culture. II. Synaptic Activity and Circuit Behavior; Journal of Neurophysiology; Vol. 40, No. 5; Sept. 1977; 1151-1162.
		DB	Ransom, B.R., et al.; Mouse Spinal Cord in Cell Culture. III. Neuronal Chemosensitivity and its Relationship to Synaptic Activity; Journal of Neurophysiology; Vol. 40, No. 5; Sept. 1977; 1163-1177.
		DC	Rees, H., et al.; Do Dorsal Root Reflexes Augment Peripheral Inflammation?; Neuro Report; Vol. 5, No. 7; 21 March 1994; 821-824.
CM		DD	Sanchez-Prieto, J., et al.; Botulinum Toxin A Blocks Glutamate Exocytosis from Guinea-Pig Cerebral Cortical Synaptosomes; Eur. J. Biochem. (1987): 165:675-681.

EXAMINER Of L	DATE CONSIDERED	4/29/05

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.: 10/630, 206
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERI- PHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP: 1653

OTHER ART (Continued)
(Including Author, Title, Date, Pertinent Pages, etc.)

	<u> </u>	DE	Shantz, E.J., et al.; Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins
1	CMK		in Medicine; Microbiol Rev.; 56:80-99 (1999).
		DF	Simpson, L.; Botulinum Toxin: Potent Poison, Potent Medicine; Hospital Practice; April 15,
ļ	- 1		1999; 34(4):87-91.
—		DG	Singh, B.R.; Critical Aspects of Bacterial Protein Toxins; Natural Toxins II (1996); Plenum
	j		Press, New York; pp. 63-84.
		DH	Tonra, J. R., et al.; Axotomy Upregulates the Anterograde Transport and Expression of
1	- 1		Brain-Derived Neurotrophic Factor by Sensory Neurons; The Journal of Neuroscience; June
	1	Ì	1, 1998; 18(11):4374-4383.
		DI	Tsuda, M., et al.; In vivo Pathway of Thermal Hyperalgesia by Intrathecal Administration of
1	1 .	Ì	αβ-methylene ATP in Mouse Spinal Cord: Involvement of the Glutamate-NMDA Receptor
Ì	j		System; Br. J. Pharmacol (1999); 127(2):449-456.
	-	DJ	Wiegand, H., et al.; The Action of Botulinum A Neurotoxin on the Inhibition by Antidromic
	- 1	1	Stimulation of the Lumbar Monosynaptic Reflex; Naunyn-Schmiedeberg's Arch. Pharmacol.
			(1977); 298:235-238.
 		DK	
		[Intramuscular Injection; Nauyn-Schmiedeberg's Arch. Pharmacol.; 292, 161-165 (1976).
		DL	Williamson, L. C., et al.; Clostridial Neurotoxins and Substrate Proteolysis in Intact
			Neurons; The Journal of Biological Chemistry; Mar. 29, 1996; Vol. 271:13; 7694-7699.
—	+	DM	Williamson, L. C., et al.; Differential Effects of Tetanus Toxin on Inhibitory and Excitatory
1			Neurotransmitter Release from Mammalian Spinal Cord Cells in Culture; Journal of
			Neurochemistry; 1992; Vol. 59:6; 2148-2157.
 	1	DN	Willis, W. D.; Pain; The Rat Nervous System; Second Edition; 1995; Academic Press, Inc.;
}	1		pages 725-750.
	+	DO	
	1		
<u> </u>		DB	The Lancet; June 5, 1999; Vol. 353; 1959-1964.
		DP	Yaksh, T. L., et al.; Chronic Catheterization of the Spinal Subarachnoid Space; Physiology &
			Behavior (1976); Vol. 17:1031-1036.
1 C	YK	DQ	Zhou et al., Biochemistry; 34:15175-15181 (1995).
	'		·

DATE CONSIDERED EXAMINER